학술논문
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Document Type
Article
Author
Cascone, T.; William, W.N.; Reuben, A.; Tran, H.T.; Fossella, F.V.; Mott, F.E.; Tsao, A.S.; Blumenschein, G.; Le, X.; Zhang, J.; Skoulidis, F.; Kurie, J.M.; Altan, M.; Lu, C.; Glisson, B.S.; Byers, L.A.; Elamin, Y.Y.; Wistuba, I.I.; Gibbons, D.L.; Heymach, J.V.; Weissferdt, A.; Kalhor, N.; Pataer, A.; Mehran, R.J.; Rice, D.C.; Walsh, G.L.; Hofstetter, W.L.; Roth, J.A.; Antonoff, M.B.; Swisher, S.G.; Vaporciyan, A.A.; Sepesi, B.; Leung, C.H.; Lin, H.Y.; Lee, J.J.; Godoy, M.C.B.; Carter, B.W.; Federico, L.; Bernatchez, C.; Khan, M.A.W.; Wargo, J.A.; Dejima, H.; Francisco-Cruz, A.; Parra, E.R.; Solis, L.M.; Fujimoto, J.; Kadara, H.; Haymaker, C.; Ajami, N.J.; Jenq, R.R.; Futreal, A.; Sharma, P.; Allison, J.P.
Source
In: Nature Medicine . (Nature Medicine, March 2021, 27(3):504-514)
Subject
Language
English
ISSN
1546170X
10788956
10788956